<DOC>
	<DOCNO>NCT00892346</DOCNO>
	<brief_summary>The clinical trial evaluate efficacy single autologous hematopoietic stem cell transplantation standard conditioning melphalan 200 mg/m2 follow thalidomide maintenance patient newly-diagnosed myeloma receive 4-6 cycle induction chemotherapy consist vincristin , adriamycin dexamethasone ( VAD ) thalidomide/dexamethasone 18 65 year .</brief_summary>
	<brief_title>Single Autologous Stem Cell Transplantation Followed Maintenance Therapy Front-line Treatment Myeloma</brief_title>
	<detailed_description>This open label clinical trial evaluate efficacy single autologous hematopoietic stem cell transplantation newly diagnose multiple myeloma patient . All patient receive 4-6 cycle induction therapy include VAD chemotherapy ( vincristin , adriamycin dexamethasone ) thalidomide/dexamethasone . After peripheral hematopoietic stem cell mobilization apheresis , patient receive standard conditioning melphalan 200mg/m2 follow thalidomide maintenance therapy 100-200mg orally daily start D+60 till disease progression untolerable toxicity .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Man woman age 1865 newly diagnose Multiple Myeloma stem cell transplantation consider appropriate Measurable serum and/or urinary paraprotein European Cooperative Oncology Group performance status 03 Serum bilirubin &lt; 1.5x upper limit normal ( ULN ) Serum alanine transaminase ( ALT ) /aspartate transaminase value &lt; 2.5 x ULN Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study Exclusion criterion : Woman child bear potential Nonsecretory MM Serum creatinine &gt; 400 Micromol/l initial resuscitation patient previous Grade 24 peripheral neuropathy Uncontrolled diabetes ( receive antidiabetic agent , subject must stable dose least 3 month first dose study drug Uncontrolled severe cardiovascular disease include myocardial infarction within 6 month enrollment , uncontrolled angina , clinically significant pericardial disease , IIIIV heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>autologous hematopoietic stem cell transplantation</keyword>
	<keyword>maintenance</keyword>
</DOC>